Our finding that the D103A mutant of mature VEGF-D exhibits enhanced potency for VEGFR-3 could be of clinical significance because this protein, or derivatives thereof, could potentially be used therapeutically to drive lymphangiogenesis and lymphatic remodeling in lymphedema and inflammatory conditions. Here, FLT4 is linked to lymphedema.